Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice?

ABSTRACT Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and whilst advances have been made in the pathophysiology, diagnostics management other podocytopathies, primary FSGS remains most elusive. It has assumed for long time that circulatory permeability factor exists mediates podocyte injury, potential autoantibody-mediated disease therefore raises question as to whether patients may benefit from targeted B-cell therapy with rituximab. The prospective case series seven by Roccatello et al. adds limited but growing evidence suggesting depletion can be safe effective treatment FSGS. In this editorial we explore available suggests how whom rituximab play role FSGS, well limitations future treatments. Further research randomized controlled trials are needed include larger numbers patients, feature genetic screening incorporate data on kinetics guide dosing frequency